Antibody drug conjugate (ADC)

Chinese flag
#AI #Antibody drug conjugate (ADC) #Biotech #China #ICON

China becoming dominant force in biotech sector, survey says 

China is emerging as a ‘global innovation powerhouse’, according to clinical research organisation ICON.  ICON’s global biotech sector survey, capturing insights from more than 260 biotech professionals and venture capital executives, found that China is cementing its dominance in the sector and Western biotechs must adapt to maintain competitiveness.  According to the survey, funding remains a key challenge, with… Read More

#Business & Investment #News

#ALS #Antibody drug conjugate (ADC) #Breast cancer #DDW Highlights podcast #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Oncology

DDW Highlights: 2 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, gene therapies provided solutions for complex conditions, most notably in Hunter syndrome… Read More

#Podcasts

#ALS #Antibody drug conjugate (ADC) #Breast cancer #Cancer research #DDW Turning Science into Business Symposium #Gene therapy #Hunter Syndrome #Neurodegenerative disorders #Oncology #The University of Manchester #University of California San Diego

This week in Drug Discovery (24 – 28 November) 

News round-up for 24 – 28 November by Bruno Quinney, Content Team at DDW.  This week in drug discovery, gene therapies are providing solutions for complex conditions, most notably in Hunter syndrome but also in amyotrophic lateral sclerosis. Elsewhere, an antibody-drug conjugate precision therapy could prevent breast cancer. … Read More

#News

Cancer cells
#Antibody drug conjugate (ADC) #Breast cancer #University of California San Diego

ADC precision therapy could prevent breast cancer, study shows 

New research has identified a precision therapy which could stop breast cancer at the source.  Researchers at the University of California San Diego School of Medicine used an antibody-drug conjugate (ADC) to target a cell-surface protein known as FZD7. FZD7 is present on cells with high tumour-initiating potential in… Read More

#Cancer Research #News

Cancer cells
#Antibody drug conjugate (ADC) #Circulating tumour cell enumeration #Oncology

Results show CTCs could be ‘dynamic biomarkers in oncology’

CellBxHealth, the company specialising in circulating tumour cell (CTC) solutions, has presented encouraging results on cell visualisation and biomarker analysis, which could shape antibody-drug conjugate (ADC) therapy.  The results, presented at the World ADC conference in San Diego, US, demonstrate successful cell visualisation and biomarker analysis across ADC targets… Read More

#Cancer Research #News

#Antibody drug conjugate (ADC) #Drug discovery #Manufacturing

Tackling ADC development 

DDW Editor Reece Armstrong speaks to Francisca Neethling, Head of Biotherapeutic Services and Olivier Mirguet, Global Head of Chemistry, at Eurofins Discovery about the challenges of antibody drug conjugate drug discovery and development and how strategies have evolved over time for these important therapies.     RA: What are some common challenges developers are facing with ADC development?   FN… Read More

#Exclusive Content

Child having ultrasound on knee
#Antibody drug conjugate (ADC) #Arthritis #Clinical trial

Lifordi begins human trial of RA treatment after positive results 

Biotechnology company Lifordi Immunotherapeutics has announced its Phase I study of rheumatoid arthritis (RA) treatment LFD-200 is underway, with positive initial results.  LFD-200 is a glucocorticoid antibody-drug conjugate (ADC) that delivers a potent steroid payload directly to immune cells, aiming to maintain the anti-inflammatory benefits of glucocorticoids… Read More

#News

GSK offices
#Antibody drug conjugate (ADC) #Cancer research #GSK

GSK buys rights to develop ADC treatment for prostate cancer 

GSK has acquired exclusive rights from biotechnology company Syndivia to develop and commercialise an antibody-drug conjugate (ADC) in prostate cancer.  The global biopharma company aims to develop the ADC for metastatic castration-resistant prostate cancer (mCRPC), which remains a significant health burden for men.  Approximately 1.4 million men worldwide are diagnosed… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Cancer research #Oncology

Antibody-drug conjugates: A targeted approach in cancer therapy

Janet Sasso, Information Scientist at CAS, provides an overview of the antibody drug conjugate market and its potential in oncology.    Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, a combination attracting growing attention in the… Read More

#Exclusive Content

Medical laboratory
#Antibody drug conjugate (ADC) #Drug discovery #India

Globalising ADC development in the US and beyond

Srivats Rajagopal explores the growth of the antibody-body conjugate (ADC) market, development trends and why innovators are turning towards India. The ADC field has reached an inflection point. In 2022, Enhertu, Kadcyla, and Trodelvy together accounted for more than $4 billion of the $4.7 billion in global ADC revenues, and over… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Molecular glue degrader #Oncology

Are DACs the new ADCs?

DDW Editor Reece Armstrong speaks to SJ Lee, Founder and CEO of Orum Therapeutics, about the potential of degrader-antibody conjugates (DACs) in treating previously “undruggable” diseases.   RA: How do DACs work? SL: Degrader-antibody conjugates (DACs) combine two proven concepts—antibody precision and catalytic protein degradation—into a single, modular medicine. First, a… Read More

#Exclusive Content

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #Organoids

Factsheet: Discover how organoids are advancing ADC research

Unlock insights into ADC development with HUB Organoids’ new factsheet on patient-derived organoids, available to download now. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy,… Read More

#News

#Antibody drug conjugate (ADC) #Drug discovery #Organoids

Advance Your ADC Research – Organoids Vs. Traditional Models

Unlock insights into ADC development with HUB Organoids’ factsheet on patient-derived organoids. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy, safety, and biomarker discovery Real-world case… Read More

#Resources

Ovarian cancer cells
#Antibody drug conjugate (ADC) #Cancer research #Financing

Tubulis raises record $361 million to develop ADC candidate TUB-040

Biotechnology company Tubulis has announced it has raised a record $361 million in financing to expand its clinical development of the antibody-drug conjugate (ADC) candidate TUB-040.  The financing represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally. The financing… Read More

#Business & Investment #News

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #eBook #Therapeutic Antibodies

eBook: The impact of ADCs on drug discovery

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. They have enjoyed considerable commercial success, particularly in treating cancer, and as a result various different types… Read More

#News